Erin Hofstatter

3.2k total citations · 1 hit paper
60 papers, 1.9k citations indexed

About

Erin Hofstatter is a scholar working on Genetics, Cancer Research and Oncology. According to data from OpenAlex, Erin Hofstatter has authored 60 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Genetics, 28 papers in Cancer Research and 20 papers in Oncology. Recurrent topics in Erin Hofstatter's work include BRCA gene mutations in cancer (20 papers), Breast Cancer Treatment Studies (19 papers) and Cancer Genomics and Diagnostics (12 papers). Erin Hofstatter is often cited by papers focused on BRCA gene mutations in cancer (20 papers), Breast Cancer Treatment Studies (19 papers) and Cancer Genomics and Diagnostics (12 papers). Erin Hofstatter collaborates with scholars based in United States, Switzerland and Germany. Erin Hofstatter's co-authors include Lajos Pusztai, Tara Sanft, Anees B. Chagpar, Christos Hatzis, Michael P. DiGiovanna, Maysa Abu‐Khalaf, Donald R. Lannin, Nina Horowitz, Brigid K. Killelea and Melinda Yushak and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and Cancer.

In The Last Decade

Erin Hofstatter

59 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of Financial Burden of Cancer on Survivors' Quality of Life

2014 360 citations Suzanne B. Evans, Michael P. DiGiovanna et al. Journal of Oncology Practice profile →

Peers

Countries citing papers authored by Erin Hofstatter

Since Specialization

Citations

This map shows the geographic impact of Erin Hofstatter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin Hofstatter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin Hofstatter more than expected).

Fields of papers citing papers by Erin Hofstatter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin Hofstatter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin Hofstatter. The network helps show where Erin Hofstatter may publish in the future.

Co-authorship network of co-authors of Erin Hofstatter

This figure shows the co-authorship network connecting the top 25 collaborators of Erin Hofstatter. A scholar is included among the top collaborators of Erin Hofstatter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin Hofstatter. Erin Hofstatter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes 2022 ·Clinical Epigenetics ·(unknown), Erin Hofstatter, Zuyun Liu, Tess A. O’Meara, Anna Maria Storniolo, D. Dalela, Vineet K. Singh, Lajos Pusztai, Morgan E. Levine	10
2	Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients 2021 ·Mayo Clinic Proceedings ·(unknown), Sandhya Pruthi, Erin Hofstatter, Dawn M. Mussallem	11
3	Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update 2019 ·Journal of Clinical Oncology ·Kala Visvanathan, Carol J. Fabian, Elissa Bantug, Abenaa M. Brewster, Nancy E. Davidson, Andrea DeCensi, Justin D. Floyd, Judy E. Garber, Erin Hofstatter, Seema A. Khan, Maria C. Katapodi, Sandhya Pruthi, (unknown), Carolyn D. Runowicz, Mark R. Somerfield	117
4	Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer 2018 ·Breast Cancer Research and Treatment ·Julia Foldi, Sarah S. Mougalian, Andrea Silber, Donald R. Lannin, Brigid K. Killelea, Anees B. Chagpar, Nina Horowitz, Courtney Frederick, (unknown), (unknown), Maysa Abu‐Khalaf, Kert D. Sabbath, Tara Sanft, Debra Brandt, Erin Hofstatter, Christos Hatzis, Michael P. DiGiovanna, Lajos Pusztai	14
5	Increased epigenetic age in normal breast tissue from luminal breast cancer patients 2018 ·Clinical Epigenetics ·Erin Hofstatter, Steve Horvath, D. Dalela, (unknown), Anees B. Chagpar, Vikram B. Wali, Veerle Bossuyt, Anna Maria Storniolo, Christos Hatzis, Gauri A. Patwardhan, (unknown), Meghan Butler, (unknown), Karen Stavris, (unknown), Alexander Au, Stephanie Kwei, Lajos Pusztai	37
6	Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer? 2017 ·The American Journal of Surgery ·Anees B. Chagpar, Nina Horowitz, Tara Sanft, Lynn D. Wilson, Andrea Silber, Brigid K. Killelea, Meena S. Moran, Michael P. DiGiovanna, Erin Hofstatter, Gina G. Chung, Lajos Pusztai, Donald R. Lannin	30
7	Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients 2017 ·The Breast Journal ·(unknown), (unknown), Olga Voznesensky, Ellen Matloff, Erin Hofstatter, Steven P. Balk, Nadine Tung	6
8	Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer 2017 ·Annals of Surgical Oncology ·Anees B. Chagpar, Christos Hatzis, Lajos Pusztai, Michael P. DiGiovanna, Meena S. Moran, Sarah S. Mougalian, Tara Sanft, Suzanne B. Evans, Erin Hofstatter, Lynn D. Wilson, Donald R. Lannin	35
9	Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer 2016 ·Clinical Cancer Research ·(unknown), Kirsten M. Timms, Anees B. Chagpar, Vikram B. Wali, Tingting Jiang, Veerle Bossuyt, Ozlen Saglam, Julia Reid, Alexander Gutin, Chris Neff, Jerry S. Lanchbury, Christos Hatzis, Erin Hofstatter, Lajos Pusztai	26
10	DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics 2016 ·Clinical Therapeutics ·Karen E. Rabenau, Erin Hofstatter	25
11	Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer 2015 ·Clinical Cancer Research ·Christos Hatzis, W. Fraser Symmans, Ya Zhang, Rebekah Gould, Stacy Moulder, Kelly K. Hunt, Maysa Abu‐Khalaf, Erin Hofstatter, Donald R. Lannin, Anees B. Chagpar, Lajos Pusztai	44
12	The benefit and burden of cancer screening in Li-Fraumeni syndrome: a case report. 2015 ·PubMed Central ·(unknown), A. Bale, (unknown), (unknown), Hari A. Deshpande, (unknown), Peter E. Schwartz, Erin Hofstatter	7
13	A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤ 25). 2015 ·Journal of Clinical Oncology ·Maysa Abu‐Khalaf, Sarah S. Mougalian, Tara Sanft, Erin Hofstatter, Gina G. Chung, Kerin B. Adelson, Andrea Silber, Debra Brandt, (unknown), (unknown), Wajih Zaheer Kidwai, Kert D. Sabbath, Michael P. DiGiovanna, William M. Sikov, Lajos Pusztai	1
14	Systematic Approach to Providing Breast Cancer Survivors With Survivorship Care Plans: A Feasibility Study 2015 ·Journal of Oncology Practice ·(unknown), Melinda L. Irwin, Anees B. Chagpar, Lajos Pusztai, Brigid K. Killelea, Nina Horowitz, Erin Hofstatter, Maysa Abu‐Khalaf, Michael P. DiGiovanna, Gina G. Chung, Tara Sanft	11
15	Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer. 2014 ·Journal of Clinical Oncology ·(unknown), Maysa Abu‐Khalaf, Christos Hatzis, (unknown), Andrea Silber, Erin Hofstatter, Tara Sanft, Raymond R. Russell	1
16	The Number of Lymph Nodes Dissected in Breast Cancer Patients Influences the Accuracy of Prognosis 2013 ·Annals of Surgical Oncology ·Lauren E. Wiznia, Donald R. Lannin, Suzanne B. Evans, Erin Hofstatter, Nina Horowitz, Brigid K. Killelea, Theodore N. Tsangaris, Anees B. Chagpar	17
17	The Promise and Pitfalls of Genomics-Driven Cancer Medicine 2013 ·The AMA Journal of Ethic ·Erin Hofstatter, A. Bale	6
18	Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists 2012 ·Current Cardiology Reviews ·Erin Hofstatter, (unknown), Kerry S. Russell, Raymond R. Russell	2
19	Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice 2011 ·Breast Cancer Research ·Laura N. Burga, Hai Hu, Ashish Juvekar, Nadine Tung, Susan L. Troyan, Erin Hofstatter, Gerburg M. Wulf	49
20	PALB2 mutations in familial breast and pancreatic cancer 2011 ·Familial Cancer ·Erin Hofstatter, Susan M. Domchek, Alexander Miron, Judy E. Garber, Molin Wang, (unknown), (unknown), Penelope Miron, Katherine L. Nathanson, Nadine Tung	94

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact